SGLT2 Inhibitors – New drugs for Type 2 Diabetes
There is a new class of medications for type 2 diabetes under investigation in diabetes clinical trials. These drugs are different from other diabetes drugs, in that, they act independently of insulin. Their specific mechanism of action is inhibition of the SGLT2 protein in the kidneys. SGLT2 is responsible for glucose reabsorption in the kidneys. SGLT2 inhibitors block this reabsorption thereby increasing the amount of glucose that is excreted in the urine. An overall reduction in blood-glucose levels is the result.
The SGLT2 inhibitors that are in current diabetes clinical trials are Empagliflozin, Ipragliflozin, Dapagliflozin, and Canagliflozin.
How Can Sleep Affect Your Chances of Developing Metabolic Disorders?
The Lancet Diabetes and Endocrinology recently reported on evidence that reduced sleep can negatively impact energy homeostasis, increasing the risk of metabolic syndrome and disorders related to glucose metabolism. Some of the mechanisms thought to be involved include: reduced insulin sensitivity, alterations in gene expression associated with circadian rhythm & metabolism, and changes in neuroendocrine signalling.
Technology now dominates our lives, and it is now finding its role in our health care. A recent clinical trial assessed the effectiveness of text messaging educational and motivational information to participants in diabetes clinical trials. The study successfully demonstrated that those who received these text messages had a reduced rate of progression to type 2 diabetes compared to those who did not receive these messages.